PMID- 30156445
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20230810
IS  - 2376-1032 (Electronic)
IS  - 2376-0540 (Print)
IS  - 2376-0540 (Linking)
VI  - 24
IP  - 9-a Suppl
DP  - 2018 Sep
TI  - Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like 
      Peptide-1 Receptor Agonists.
PG  - S14-S29
LID - 10.18553/jmcp.2018.24.9-a.s14 [doi]
AB  - This article provides an overview of the efficacy and safety of once-weekly 
      glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of type 2 
      diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic GLP-1 receptors, which 
      increases insulin secretion, delays gastric emptying, and increases satiety. As a 
      class, GLP-1 RAs lower A1c levels and have been associated with reductions in 
      weight and blood pressure and reduced fluctuations in glucose levels, and they 
      have a low risk of hypoglycemia. Exenatide extended release (ER) and dulaglutide 
      monotherapy have shown similar or superior reductions in A1c and weight compared 
      with various oral antidiabetic drugs (OADs). Semaglutide has been shown to reduce 
      both A1c and body weight compared with placebo and, in head-to-head studies 
      versus both exenatide ER and dulaglutide, showed greater reductions in A1c and 
      body weight. Once-weekly GLP-1 RAs have also been evaluated as add-on therapy in 
      the continuum of care for the treatment of T2DM in combination with a variety of 
      background medications, including 1 or more OADs (metformin, sulfonylureas, 
      and/or thiazolidinediones), basal insulin, and prandial insulin. Gastrointestinal 
      adverse events (e.g., nausea, vomiting, and diarrhea) are the most common side 
      effects with once-weekly GLP-1 RAs. Rates of hypoglycemia, and especially 
      major/severe hypoglycemia, are low with once-weekly GLP-1 RAs but, as expected, 
      are higher when used in combination with sulfonylureas or insulin. These 
      once-weekly GLP-1 RAs provide a safe and effective treatment option for patients 
      with T2DM and may offer improved convenience and possibly greater adherence 
      compared with daily GLP-1 RAs. DISCLOSURES: This supplement was funded by Novo 
      Nordisk. Handelsman reports research grants from Amgen, AstraZeneca, 
      Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Janssen, Lexicon, Merck, 
      Novo Nordisk, Regeneron, and Sanofi; speaker fees from Amarin, Amgen, 
      AstraZeneca, Boehringer Ingelheim-Lilly, Janssen, Merck, Novo Nordisk, Regeneron, 
      and Sanofi; and has served in advisory capacity to Amarin, Amgen, AstraZeneca, 
      Boehringer Ingelheim, Eisai, Intarcia, Janssen, Lilly, Merck, Merck-Pfizer, Novo 
      Nordisk, Regeneron, and Sanofi. Cannon reports speaker fees and owns stock in 
      Novo Nordisk. Shannon reports consultant and speaker fees from Novo Nordisk and 
      Boehringer Ingelheim-Lilly Alliance. Schneider reports advisory board fees from 
      Intarcia, Lilly, and Novo Nordisk. Wyne has nothing to disclose.
FAU - Handelsman, Yehuda
AU  - Handelsman Y
AD  - 1 Metabolic Institute of America, Tarzana, California.
FAU - Wyne, Kathleen
AU  - Wyne K
AD  - 2 The Ohio State University Wexner Medical Center, Columbus.
FAU - Cannon, Anthony
AU  - Cannon A
AD  - 3 Private Practice, Hamilton, New Jersey.
FAU - Shannon, Michael
AU  - Shannon M
AD  - 4 PMG Olympia Endocrinology, Lacey, Washington.
FAU - Schneider, Doron
AU  - Schneider D
AD  - 5 Jefferson Health at Abington Hospital, Abington, Pennsylvania.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Manag Care Spec Pharm
JT  - Journal of managed care & specialty pharmacy
JID - 101644425
RN  - 0 (Blood Glucose)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 9P1872D4OL (Exenatide)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
EIN - J Manag Care Spec Pharm. 2018 Nov;24(11):1196a. PMID: 30806138
MH  - Blood Glucose/*drug effects/metabolism
MH  - Body Weight/drug effects/*physiology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Administration Schedule
MH  - Exenatide/administration & dosage
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/*physiology
MH  - Glucagon-Like Peptides/administration & dosage/analogs & derivatives
MH  - Glycemic Index/drug effects/physiology
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Immunoglobulin Fc Fragments/administration & dosage
MH  - Recombinant Fusion Proteins/administration & dosage
MH  - Treatment Outcome
PMC - PMC10408429
COIS- This supplement was funded by Novo Nordisk. Handelsman reports research grants 
      from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, 
      Janssen, Lexicon, Merck, Novo Nordisk, Regeneron, and Sanofi; speaker fees from 
      Amarin, Amgen, AstraZeneca, Boehringer Ingelheim-Lilly, Janssen, Merck, Novo 
      Nordisk, Regeneron, and Sanofi; and has served in advisory capacity to Amarin, 
      Amgen, AstraZeneca, Boehringer Ingelheim, Eisai, Intarcia, Janssen, Lilly, Merck, 
      Merck-Pfizer, Novo Nordisk, Regeneron, and Sanofi. Cannon reports speaker fees 
      and owns stock in Novo Nordisk. Shannon reports consultant and speaker fees from 
      Novo Nordisk and Boehringer Ingelheim-Lilly Alliance. Schneider reports advisory 
      board fees from Intarcia, Lilly, and Novo Nordisk. Wyne has nothing to disclose.
EDAT- 2018/08/30 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/09/01
CRDT- 2018/08/30 06:00
PHST- 2018/08/30 06:00 [entrez]
PHST- 2018/08/30 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - 10.18553/jmcp.2018.24.9-a.s14 [doi]
PST - ppublish
SO  - J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S14-S29. doi: 
      10.18553/jmcp.2018.24.9-a.s14.